Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips for teeth whitening. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, that is in phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed phase II a clinical ...
235 Constitution Drive
Menlo Park, CA 94025
Founded in 1995
Corium International Files Shelf Registration; Mulls Acquisitions
Dec 30 15
Corium International, Inc. (NasdaqGM:CORI) filed a Shelf Registration in the amount of $76.42 million. The company intends to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research and development, increasing our working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies that are complementary to our own and capital expenditures.
Corium International, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015; Provides Earnings Guidance for the Year 2016
Nov 12 15
Corium International, Inc. announced unaudited earnings results for the fourth quarter and full year ended September 30, 2015. For the quarter, the company reported total revenues of $9,266,000 against $11,072,000 a year ago. Loss from operations was $6,690,000 against $4,797,000 a year ago. Loss before income taxes was $8,634,000 against $6,366,000 a year ago. Basic and diluted net loss attributable to common stockholders was $8,635,000 against $6,367,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.42 against $0.35 a year ago. The decrease in total revenues primarily resulted from declining product revenues from Fentanyl TDS (marketed by Par Pharmaceutical) and Clonidine TDS (marketed by Teva Pharmaceuticals), partially offset by growth in contract research and development revenues. Product revenues for the quarter were $6.0 million compared with $9.0 million in 2014.
For the year, the company reported total revenues of $40,921,000 against $42,440,000 a year ago. Loss from operations was $21,024,000 against $10,050,000 a year ago. Loss before income taxes was $28,447,000 against $9,911,000 a year ago. Basic and diluted net loss attributable to common stockholders was $28,450,000 against $9,912,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $1.52 against $0.99 a year ago. Revenue was primarily due to expected declines in product revenues from both Clonidine TDS (marketed by Teva Pharmaceuticals) and Fentanyl TDS (marketed by Par Pharmaceutical), partially offset by an increase in contract research and development revenues from co-development programs and new partner-funded programs. In addition, revenues for the fiscal year ended September 30, 2014, included recognition of $1.8 million in non-cash product revenue that had been previously deferred since 2007. The recognition of this revenue related to the expiration of a contractual liability, and does not have an impact on revenues after fiscal 2014. Product revenues for the year were $26.5 million compared with $32.2 million in 2014.
The company currently anticipates that 2016 revenues could be between 80% and 120% of 2015 revenues. The company expects R&D expenses and G&A expenses continue to increase.
Corium International, Inc. to Report Q4, 2015 Results on Nov 12, 2015
Nov 5 15
Corium International, Inc. announced that they will report Q4, 2015 results at 5:00 PM, Eastern Standard Time on Nov 12, 2015